UPC CoA 405/2024
Jul 11, 2024·EP3167888 Unitary patent · TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
- Case details
- StatusCase ClosedActionAppealCategoryMain appeal
- Parties
- Claimants
- Alexion Pharmaceuticals, Inc.Operating co.
Representatives- Elena Hennecke-Freshfields
- Wolrad Prinz zu Waldeck Und Pyrmont-Freshfields
- Christopher Stothers-Freshfields
- Gregor König-König Szynka - Tilmann - Von Renesse
- Claudia Hertzsch-König Szynka - Tilmann - Von Renesse
Respondents- Amgen Technology (Ireland) Unlimited CompanyOperating co.
Representatives- Tilman Mueller-Stoy-Bardehle Pagenberg
- Tobias Wuttke-Bardehle Pagenberg
- Tim Harris-Osborne Clark
- Dominik Woll-Bardehle Pagenberg
- Axel Berger-Bardehle Pagenberg
- Markus Ackermann-Bardehle Pagenberg
- Division
- Court of Appeal
- Technology
- ChemistryBiotechnology · Pharmaceuticals
- Language
- English
- First decided
- Jul 30, 2024
- Last decision
- Jun 19, 2025
- EPO Opposition
- Samsung Bioepis NL B.V.Withdrawn2024-05-02
- Amgen Technology (Ireland) Unlimited CompanyWithdrawn2024-10-28
- Salute HC Ilaç Pazarlama A.S.Admissible2025-01-31
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Judge Rian Kalden | Locked |
| Judge Patricia Rombach | Locked |
| Judge Ingeborg Simonsson | Locked |
At the UPC: AstraZeneca Group (13 cases)·Amgen Group (19 cases)
This dispute contains 2 other proceedings
6 other defendants litigating the same or a related patent
UPC CoA 744/2025·UPC CFI 674/2025·UPC CFI 51/2025·UPC CFI 642/2024·UPC CoA 402/2024 and 1 more
Start a free trial to see how each one ended.
More cases: Court of Appeal·2024
- 2025-06-19
Summary: The Court of Appeal set out general principles for rehearing applications under Art. 81(1)(b) UPCA, establishing that only fundamental procedural defects that would have led to a different outcome can justify rehearing, in proceedings where Alexion sought to reopen a dismissed provisional measures appeal against Amgen concerning EP 3 167 888.
Show the legal issues (3)
- Rehearing application (Art. 81(1) UPCA, R. 245 RoP)
- Fundamental procedural defect
- Standard for reopening final decisions
- 2024-12-20Appeal RoP220.1Public
Summary: The Court of Appeal dismissed Alexion's appeal against the first-instance refusal of provisional measures, upholding the finding that the patent claim could not be corrected by interpretation to remove alleged errors, and confirming that claim 2 of EP 3 167 888 was more likely than not insufficiently disclosed (Article 83 EPC). The provisional measures application was therefore denied.
Show the legal issues (5)
- Claim interpretation — correction of errors
- Insufficiency of disclosure (Article 83 EPC)
- Provisional measures
- Claim interpretation from perspective of skilled person
- Patent prosecution history (TBA proceedings)
- 2024-08-08
Summary: The Court of Appeal ruled that service of written pleadings must be effected through the Court's electronic CMS and that prior communication via Germany's beA (besonderes elektronisches Anwaltspostfach) does not constitute effective service under R.278.1 RoP.
Show the legal issues (4)
- Service of documents
- R.278.1 RoP
- Electronic CMS service
- beA (besonderes elektronisches Anwaltspostfach)
- 2024-07-30
Summary: The Court of Appeal rejected Alexion Pharmaceuticals' request to expedite the appeal against the Hamburg Local Division's refusal to grant provisional measures against Amgen, holding that the circumstances were not sufficiently urgent to justify shortening the time period for the respondents to lodge their statement of response.
Show the legal issues (5)
- Expedition of appeal
- R.9.3(b) RoP
- Shortening of deadlines
- Provisional measures appeal
- R.225(e) RoP
| Document title | Date | Public |
|---|---|---|
| Cover sheet | 2025-11-25 | Not public |
| Other document Appellant | 2025-11-25 | Not public |
| Receipt | 2025-11-25 | Not public |
| 20250721_Confidentiality_Request_re_Application_cost_decision_rehearing | 2025-07-21 | Not public |
| 20250721_Confidentiality_Request_re_Application_cost_decision_rehearing | 2025-07-21 | Not public |
| 20250721_Application_cost_decision_rehearing_Confidential | 2025-07-21 | Not public |
| Headnote-and-Keywords | 2025-06-19 | Not public |
| Outcome of the Order | 2025-06-19 | Not public |
| Decision | 2025-06-19 | Public |
| Exhibit_BP_33_Amgen_en | 2025-05-12 | Not public |